Skip to search formSkip to main contentSkip to account menu

nivolumab

Known as: NIVO 
A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death… 
National Institutes of Health

Related topics

Related topics

6 relations
10 ML nivolumab 10 MG/ML Injection [Opdivo]Monoclonal AntibodiesNCIt Antineoplastic Agent Terminologyantigen binding

Broader (1)

Antineoplastic Agents

Narrower (1)

MDX-1106

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).
3514 Background: mCRC remains a lethal cancer and immunotherapy in MSS mCRC has yet to show significant activity. In preclinical… 
2018
2018
Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.
3013Background: IPI-549 is a potential first-in-class, oral, selective PI3K-γ inhibitor that in preclinical studies reprograms… 
2017
2017
A case of new‐onset antibody‐positive myasthenia gravis in a patient treated with pembrolizumab for melanoma
1. Becker PE. Myotonia congenita and syndromes associated with myotonia: clinical-genetic studies of the nondystrophic myotonias… 
2017
2017
Case of type 1 diabetes associated with less‐dose nivolumab therapy in a melanoma patient
gates of foamy histiocytes in the dermis and verrucous acanthosis. Regarding its pathogenesis, it is thought that the epithelial… 
Review
2017
Review
2017
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.
2016
2016
Nivolumab-induced thyroid dysfunction.
Nivolumab (ONO-4538) is an anti-programmed death-1 specific monoclonal antibody, which has become a standard treatment for… 
Highly Cited
2016
Highly Cited
2016
Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.
6 Background: Patients (pts) with GC/GEC often present with A/M disease, which has a poor prognosis, with 1-year survival < 30… 
2016
2016
Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.
4501Background: Minimal antitumor activity of existing therapies and the observation of immune dysfunction in bladder cancer have… 
2016
2016
Perspective: What next for treatment?
We need to focus on five main areas to make real progress in the treatment of kidney cancer, says Robert J. Motzer. 
Highly Cited
2014
Highly Cited
2014
Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.
5012 Background: Nivolumab, a fully human IgG4 programmed death-1 (PD-1) inhibitor antibody, has shown encouraging activity in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)